625 results on '"Hanauer, S"'
Search Results
2. P1074 Impact of body mass index (BMI) on clinical outcomes and drug levels in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study
3. DOP64 Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trial
4. P734 Super-responders in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD study
5. P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials
6. P1009 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
7. P623 Network meta-analysis to evaluate the comparative efficacy of advanced therapies as first line for maintenance treatment of adult patients with moderate-to-severe Crohn’s disease
8. P874 Impact of immunogenicity on clinical outcomes in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study
9. P902 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study
10. P790 Assessment of steroid use in patients with active ulcerative colitis who initiated a new Janus kinase inhibitor or tumour necrosis factor inhibitor using data from a United States claims database
11. P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study
12. P983 Treatment of patients with moderate-to-severe Crohn’s disease with subcutaneous infliximab leads to an endoscopic response across all segments of the colon and terminal ileum: A post hoc analysis of the LIBERTY-CD study
13. P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study
14. P814 Clinical trial design in Crohn’s disease: interpreting future endpoints based on post hoc analyses of the vedolizumab phase 3 trials GEMINI 2 and VISIBLE 2
15. Ozanimod as induction and maintenance therapy for ulcerative colitis
16. DOP024 Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2
17. Long‐term safety of adalimumab in clinical trials in adult patients with Crohnʼs disease or ulcerative colitis
18. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus
19. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases:an International Organization for Study of Inflammatory Bowel Diseases consensus
20. P119 Higher levels of infliximab may alleviate the need of azathioprine comedication in the treatment of patients with Crohnʼs disease: a SONIC post hoc analysis
21. OP014 Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension
22. Induction of remission in ulcerative colitis
23. DOP81 Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn’s Disease in the SERENE studies
24. P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative Colitis
25. P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study
26. Potential human models of IBD
27. Computer-Assisted Instruction in the Pronunciation of Foreign Languages.
28. Ozanimod for moderate-to-severe Ulcerative Colitis (UC): efficacy, safety, and histology results from the induction and maintenance periods of the Phase 3 TRUE NORTH Study
29. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohnʼs disease
30. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans
31. OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study
32. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohnʼs disease
33. State-of-the-Art Lecture: The future of biologic therapy in Asia
34. Commentary: pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis
35. Can we treat ulcerative colitis with nutritional supplements?
36. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis - additional results from two controlled studies
37. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohnʼs disease
38. Evaluation of a daily practice composite score for the assessment of Crohnʼs disease: the treatment impact of certolizumab pegol
39. Randomised clinical trial: certolizumab pegol for fistulas in Crohnʼs disease – subgroup results from a placebo-controlled study
40. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease
41. Review article: evolving concepts in treatment and disease modification in ulcerative colitis
42. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
43. European evidence-based consensus on the diagnosis and management of Crohn’s disease
44. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis
45. New lessons: classic treatments, expanding options in ulcerative colitis
46. Pilot Study On Safety And Effectiveness Of Selective Granulocyte/Monocyte Apheresis In Patients With Inflammatory Bowel Disease: SP25
47. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine
48. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohnʼs disease
49. Budesonide as maintenance treatment in Crohnʼs disease: a placebo-controlled trial
50. the long-term management of ulcerative colitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.